Free Trial

Nyxoah Q3 2024 Earnings Report

Nyxoah logo
$6.99 +0.49 (+7.54%)
As of 04:00 PM Eastern

Nyxoah EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.46
Beat/Miss
Missed by -$0.22
One Year Ago EPS
-$0.29

Nyxoah Revenue Results

Actual Revenue
$1.73 million
Expected Revenue
$1.47 million
Beat/Miss
Beat by +$260.00 thousand
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q3 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Nyxoah Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Kepler Capital Remains a Buy on Nyxoah (NYXH)
HC Wainwright Has Positive Outlook for Nyxoah Q1 Earnings
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

View Nyxoah Profile

More Earnings Resources from MarketBeat